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Abstract 
Background: New psychoactive substances (NPS) are on offer worldwide online, in order to 
shed light on the purity and price of these substances in the European Union, a research 
collaboration was set up involving France, United Kingdom (UK), the Netherlands, Czech 
Republic and Poland.  
Methods: Per country, around 10 different NPS were test purchased from different webshops. 
Then, chemical analysis of NPS was done with according reference standards to identify and 
quantify the contents.  
Results: In contrast to what is generally advertised on the webshops (>99%), purity varied 
considerably per test purchased NPS. Several NPS were mislabelled, some containing 
chemical analogues (e.g. 25B/C-NBOMe instead of 25I-NBOMe, pentedrone instead of 3,4-
DMMC). But in some cases NPS differed substantially from what was advertised (e.g. 
pentedrone instead of AMT or 3-FMC instead of 5-MeO-DALT). Per gram, purity-adjusted 
prices of cathinones differed substantially between three countries of test purchase, with 
Poland being the least expensive. Synthetic cannabinoids were relatively the most expensive 
in the Czech Republic and least expensive in the UK.  
Conclusions: The current findings provides a snapshot of the price and chemical contents of 
NPS products purchased by different countries and in different webshops. There is a potential 
danger of mislabelling of NPS. The great variety in price and purity of the delivered products 
might be the result of the market dynamics of supply and demand and the role of law 
enforcement in different European countries. 
 
Keywords: webshops; NPS; purity; price; chemical analysis; European Union 
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Introduction 
In recent years, the worldwide illicit drug market is characterized by a continuous 
emergence of the marketing and sale of newly designed psychoactive substances mimicking 
the effects of internationally controlled substances (such as cocaine, ecstasy or 
amphetamine). These new psychoactive substances (NPS) arise from entrepreneurial 
endeavours where ideas for their creation are inspired by patents, scientific literature, existing 
controlled drugs of abuse and medicines known to have psychoactive properties (Brandt, 
King, & Evans-Brown, 2014). For instance, some NPS follow similar molecular scaffolds as 
their illicit counterparts but might slightly differ in chemical composition of the molecule 
(Saha et al., 2015; Simmler et al., 2013). These alterations can impact greatly on the specific 
activities of a compound. For instance, neurotransmitter transporter affinity could be 
significantly altered, resulting in substances that block serotonin or dopamine reuptake more 
effectively (Baumann et al., 2014; Marusich et al., 2014; Saha et al., 2015). Whereas many of 
these alterations were designed to circumvent law enforcement, they could have a grave 
impact on the health of the drug user, like an increased risk of overdosing.  
Increasing awareness about harms associated with NPS use also requires a multi-
disciplinary and targeted approach (European Monitoring Centre for Drugs and Drug 
Addiction, 2016a). The diversity of substances has increased dramatically in the last few 
years. This is reflected in the number (> 560) and nature of substances currently monitored by 
the European Union’s Early Warning System that is coordinated by the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA). Among a range of other substances, types 
of compounds frequently recorded include cathinones, opioids, benzodiazepines or synthetic 
cannabinoids (a chemically highly diverse groups of compounds) (EMCDDA Europol, 2016).  
The sale of these substances is mostly facilitated through freely accessible Internet shops 
(webshops). In 2013, the EMCDDA conducted a snapshot study which revealed 651 different 
webshops offering a variety of NPS globally (European Monitoring Centre for Drugs and 
Drug Addiction, 2016b). Some of these substances are also being sold by vendors through the 
dark web, an Internet space not accessible with standard search engines (Barratt et al., 2016). 
Recent research identified 1031 different vendors on the dark web selling substances and 
10,927 individual drug listings (Aldridge et al., 2016). However, vendors on the dark web also offer 
many other substances too, including illicit substances, and most of the 10,927 drug listings fell into 
either of six categories: psychedelics, stimulants, opioids, cannabis, ecstasy and prescription drugs. 
NPS were mainly found under psychedelics or stimulants. 
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From a health policy and clinical perspective, there is great concern surrounding the rapid 
emergence of NPS, their lack of regulation, open sale and a lack of evidence on their effects and 
harms (Coulson & Caulkins, 2012; European Monitoring Centre for Drugs and Drug Addiction, 2015; 
Seddon et al., 2014; UNODC, 2013; van Amsterdam, Nutt, & van den Brink, 2013). Besides this, 
there is the risk of mislabelling with NPS available through freely accessible websites which 
are virtually uncontrolled and unlimited. Well-known examples of false and misleading labelling 
is by giving these drugs meaningless and generic brand names, like “spice” or “K2” (Baumann et al., 
2014; Baumann, Partilla, & Lehner, 2013; Seely et al., 2013; Spaderna, Addy, & D’Souza, 2013). 
However, mislabelling by selling one compound as another also occurs and can be equally or more 
dangerous. Several recent cases have been noted where very potent compounds were sold as less 
potent analogues, increasing the risk of dosage-related adverse effects (Gee, Schep, Jensen, Moore, & 
Barrington, 2016; Walterscheid et al., 2014).  
As a result, stakeholders associated with healthcare, forensics and policy-making are 
continuously faced with the challenge of collecting evidence for risk assessments of these 
unknown substances (Zamengo, Frison, Bettin, & Sciarrone, 2014). Another issue that has 
been raised in recent years is the difficulty in the identification of NPS in seized samples or 
biological specimens, as their variation is ever-increasing and routine toxicological laboratory 
screenings are not always up to the challenge of keeping track of the rapid emergence of 
these new substances or their metabolites (Favretto, Pascali, & Tagliaro, 2013). Standard 
immunoassay methodology often does not discriminate between all these molecular variants 
of chemical classes of NPS. In addition, absence of appropriate reference material and scarce 
analytical information about newly encountered NPS adds challenges even in the presence of 
state-of-the-art instrumentation. Furthermore, such systems may be out of reach for 
laboratories that are situated in economically less privileged countries, meaning that many 
NPS go undetected and are not reported to early warning systems operating worldwide 
(UNODC, 2013).  
The availability of substances, popularity, prevalence of use and distribution of NPS, 
however, is not necessarily identical in each country and reasons for this might include 
cultural differences, geographical location and different legislation (UNODC, 2016). In order 
to shed light on the diverse nature of NPS distribution and newly emerging drugs that are 
being offered through online shops across European countries, an international research 
collaboration was supported by the European Commission to investigate the online NPS 
market. Entitled the Internet Tools for Research in Europe on New Drugs (I-TREND, www.i-
trend.eu), the project involved five collaborating institutions in different countries: 
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Observatoire français des drogues et des toxicomanies (OFDT) in France, Liverpool John 
Moores University (LJMU) in the United Kingdom (UK), the Netherlands Institute of Mental 
Health and Addiction (Trimbos institute) in the Netherlands, the Charles University in Prague 
(CUNI) of the Czech Republic and the SWPS University of Social Sciences and Humanities 
(SWPS) in Poland. This collaborative endeavour was undertaken between 2014-2015 and 
collected a variety of data on NPS, such as availably and marketing of NPS via online 
European webshops and the chemical analysis of NPS that were purchased online (for more 
details of the general scheme, see 
http://www.emcdda.europa.eu/system/files/publications/2155/TDXD16001ENN_FINAL.pdf)
. In the present study, the chemical analysis part of the project is described to identify the 
contents of the ten most relevant NPS purchased per country. This is followed by an analysis 
of average purity, price and adulteration of the test purchased NPS products and identification 
of potential mismatch between contents and the product advertised (mislabelling). 
 
Methods 
Selection of NPS and webshops 
Each partner country selected about ten NPS (aka the Top List) on the basis of available 
information sources. Firstly, data from the national Reitox European Union Early Warning 
System (EU EWS) were consulted. It reports on police seizures, fatal and non-fatal 
intoxication data, as well as forensic and toxicological data when available. Secondary, when 
the EWS data was not considered useful or retrieved too little information, extensive data 
were collected from national poisoning information centres (e.g. National Poisons 
Information Service, UK), national (e.g. British Crime Survey in the UK), international drugs 
surveys (the Global Drug Survey), drug user forums and drug sampling data from nationally 
imbedded drug testing systems (e.g. DIMS in the Netherlands or SINTES in France) 
(Giraudon and Bello, 2009; Niesink and Brunt, 2011; Global Drug Survey, 2016; Office for 
National Statistics, 2016).  
Then, webshops were selected for ordering the NPS. Server location and IP address were 
not the most reliable criteria for the selection of webshops for the different partner countries, 
as various webshops hold servers abroad and due to the nature of the online market, which is 
unbound and not restricted by the same rules that apply to the domestic wholesale market. 
Therefore, the criteria for webshop selection were the language in which the webshop 
presented itself, advertised its products and its shipment constrictions, which indicated at 
6 
 
which consumer market it was predominantly targeted. Also, only webshops that were 
accessible on the surface web were selected, cryptomarkets on the dark web were excluded. 
Another selection criterion was that the webshops would sell and promote one of the NPS 
selected, this confined the search to a proportion of available webshops. The largest and 
highest google-indexed webshops were chosen on the basis of this. In order to avoid legal 
problems with purchasing substances, it was decided to preferably order NPS not controlled 
at the time of purchase. 
In some instances, webshops were selling and promoting newly synthesized compounds as 
replacements for substances just put under control (for instance, when a substance had been 
implicated in a fatal intoxication). Whether such substances often emerged too recent to be 
found in seizure data, they were included in a national NPS Top List anyway to acknowledge 
this issue. For example, both 5- and 6-APB were initially included in the UK Top List based 
on seizure data. However, due to their rapid inclusion into legislative control (The Stationery 
Office, 2013), availability and advertisement on UK-based webshops decimated. Between the 
announcement of the 5/6-APB ban and its definitive confirmation, the ‘follow-up’ substance 
5-EAPB was highly being discussed about on British forums as 5/6-APB replacement and 
also being sold and promoted on UK webshops and this NPS was thus included in the UK 
Top List of test purchases instead. Notably, synthetic cannabinoids were not selected by the 
Netherlands in this study, since there was an absence of webshops marketing these substances 
in the Netherlands and the virtual absence of synthetic cannabinoids in the Dutch EWS and 
DIMS data. 
 
Test purchases 
Each I-TREND partner separately purchased NPS from webshops using a variety of 
payment methods, such as prepaid credit card, credit cards or bank wire transfer (e.g. through 
PayPal). It was also aimed to avoid traceability to the institutions in order to maintain 
appearance as individual customers. The Top List contained test purchases of around 10 NPS 
per country and it was strived to test purchase these at 4 different webshops, resulting in 40 
NPS test purchases per partner institute. In the case of non-reception of the parcel there was 
no further follow-up or contact with the supplier.  
The Trimbos institute in the Netherlands formed an exception to this purchasing process, 
since it has its continuous flow of NPS drug samples through the Drug Information and 
Monitoring System (DIMS) and it was expected that all NPS of the Top List would be 
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handed in during the two-year period of sample collection. For a description of the DIMS, see 
(Niesink and Brunt, 2011). At the DIMS, specifically for the I-TREND project, the drug 
consumers were asked additional questions, such as source of purchase on the Internet 
(webshops) and price. Samples without this information, or samples not purchased from the 
Internet, were excluded from the study.  
Laboratory analysis 
Reference standards (50 mg) for the different NPS were obtained from LGC standards
TM
 
(LGC Standards, Middlesex, Teddington, UK). Both qualitative and quantitative 
examinations of the received NPS were employed using standard methods of analysis, such 
as gas chromatography and liquid chromatography (LC) coupled to mass spectrometry (MS) 
and LC and GC combined with diode array detection (DAD) or flame ionization detector 
(FID). Shortly, CUNI, SWPS, DIMS, LJMU and OFDT used LC-MS, LC-MS/MS, LC-
DAD, GC-MS and GC-FID. For some compounds, OFDT, CUNI and SWPS also used GC 
and Quadrupole Time-of-Flight (QTOF) methodology and GC-MS/MS for better 
identification and quantification. Basically, most quantitative methods overlapped between 
all laboratories and this wasn’t expected to have a major impact on the results (see Table S5 
for overview of laboratory techniques). 
 
Price analysis 
Prices of the different NPS purchased from webshops were compared. British Pound 
Sterling (GBP), Czech Koruna (CZK) and Polish Zloty were converted to Euro, based on the 
average currency exchange rate between June 2014 and February 2015, the time during 
which the online test purchases were conducted. Average prices of NPS per gram per 
country, average price per NPS and average price overall were calculated. In addition, purity 
adjusted prices were also calculated per individual NPS, consistent with procedures reported 
in the scientific literature about drug market dynamics (Caulkins et al., 2007). In addition, 
prices were converted into purchasing power parities (PPPs), an economic measure that’s 
designed to compare prices between different countries. PPPs serve as a way to take gross 
domestic product and inflation into account for a certain country based on goods that are 
highly comparable. For this study, NPS prices were adjusted with Eurostat-published PPP for 
alcohol, tobacco and narcotics, in order to estimate the relative price of NPS in comparison 
with their nearest substitute goods (Eurostat-OECD, 2012). Standard deviations (± S.D.) are 
given. 
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Results 
The number of webshops selected for test purchase varied per country: The Netherlands 
(20), United Kingdom (5), France (11), Czech Republic (6), Poland (5). Most webshops had 
IP addresses that indicated that they originated from the countries of test purchase, except for 
France, which had no webshops originating from that country. Instead, all their purchases 
came from webshops located in the UK, but their IP address was different from those of the 
webshops which the UK selected. Moreover, there were no overlapping webshops between 
countries based on IP address. Most webshops advertised their NPS products as >90% pure 
or higher. In total, 200 NPS products were test purchased by the 5 partner countries under 31 
different chemical NPS names. Chemical names, abbreviations, chemical class and main 
effect of these 31 NPS are given in Table 1. Eighteen orders were never delivered and one 
analysis had not been performed by the laboratory. Consequently, 182 analyses were 
conducted and 34 different compounds identified. 15 NPS were obtained by more than one 
partner country, whereas 16 NPS were unique to a specific country (Table 2).  
 
Chemical content 
Twenty-six products were test purchased multiple times from different webshops and 
analysed by the different country laboratories. The average purity (%) values of 24 NPS 
powders is shown in Fig. 1. Most powders showed a relatively high purity of 65% or above, 
except for pentedrone, 6-APB, AM-2201 and UR-144. Etizolam and 25I-NBOMe were sold 
in tablet form or on blotters, respectively. The average 25I-NBOMe content on blotters (n=4) 
was 835 g/ blotter and the average etizolam content in the tablets (n=8) was 1.03 mg/ tablet. 
Purity varied considerably per NPS, in contrast to what was advertised on most webshops 
(>90-99% purity). Purity also differed per country of purchase, with the UK showing the 
highest purity (>90%) and Poland the lowest (<60%). 
The extent of mislabelling was also determined, mislabelling was defined as ‘not 
containing the advertised substance at all’. Several examples of mislabelled NPS were 
encountered (Fig. 2). Mainly, 25I-NBOMe, 3-MMC, 3,4-DMMC and 5-APB samples were 
mislabelled, but contained chemically similar analogues (e.g. 25B/C-NBOMe instead of 25I-
NBOMe, 4-MEC instead of 3-MMC, pentedrone instead of 3,4-DMMC and 6-APB instead 
of 5-APB, respectively). Likewise, most other mislabelled products tended to contain 
chemically related NPS, but in some cases the detected content differed substantially from 
what was advertised (e.g. pentedrone instead of AMT or 3-FMC instead of 5-MeO-DALT). 
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Test purchases in Poland revealed the highest proportion of mislabelling (33%), whereas 
samples purchased in the UK all corresponded to what was advertised. There were twenty 
instances whereby a product contained more than one single NPS, which was not advertised 
as such on the website. In all of the cases, samples primarily contained the advertised NPS, 
with a small percentage (<15%) of an additional NPS as adulterant. 
 
Price 
On average, the price of a NPS product was € 22.73 ± 13.2 (median € 17.43) and some 
NPS were relatively more expensive compared to others (e.g. methoxphenidine, AMT or 5-
EAPB) (Fig. 3). For comparability, it was decided to compare price within the same chemical 
NPS class. In the three countries that test purchased cathinones, prices differed substantially, 
with Poland having the relatively lowest price (Table 3). Prices of synthetic cannabinoids also 
differed between countries of purchase, with the UK having the lowest nominal average price 
and remaining lowest after PPP adjustment (Table 4). Such adjustment not only reflects the 
price levels in each of the I-TREND countries (and notably: the prices compared to the 
nearest substitute substances like alcohol, tobacco and illicit drugs), but also demonstrates 
NPS availability for a consumer in each country. 
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Discussion 
This study has shown chemical analysis results for 31 different NPS test purchased across 
5 different European countries as part of the EU commissioned research project, I-TREND. 
Contrary to what is often claimed by webshops and often believed by drug users (Carhart-
Harris, King, & Nutt, 2011), the study found that not all the test purchased NPS contained the 
pure, or nearly pure, product as advertised. Sample purity varied highly between the different 
NPS, possibly reflecting the adjustment to factors like availability or response to (in)stability 
of the drug market per specific country. As another market “good”, purity and price of NPS 
maybe subject to largely the same processes as illicit substances and follow the same supply-
and-demand dynamics (National Research Council, 2010), thereby explaining variation. 
However, it may also reflect the degree to which certain NPS were already under scrutiny by 
the Council of the European Union or the World Health Organisation Expert Committee 
(WHO) (European Commission, 2015; World Health Organization, 2015). For instance, the 
UK generally showed a high purity of NPS, but this may be due to the fact that none of these 
substances were the focus of discussion questioning their legality at the time of test 
purchasing samples for this project (European Commission, 2015; World Health 
Organization, 2015). In other instances, webshops may have already stopped the sale of 
certain NPS in the wake of forthcoming legislation (e.g. 25I-NBOMe, MDPV or 
methoxetamine). These matters left aside, differences in purity might also reflect an attempt 
to provide good quality products and to remain competitive in a highly dynamic and quickly 
changing market like the Internet. 
Secondly, the results of this study highlight that a considerable proportion of NPS was 
mislabelled by the webshops. In most instances, highly similar NPS analogues were sold 
instead of the specific compounds advertised. For example, samples contained pentedrone 
instead of ethylcathinone. But in some cases, the contents was entirely different to the one 
advertised. This may lead to users ingesting substances with unanticipated effects and 
possibly different effective doses, which can cause serious harm. For instance, -PVP is a 
much more potent stimulant than 4-FA and it was present in one sample advertised as 4-FA. 
In previous research mislabelling of street drugs has been shown multiple times with fatal 
consequences. For instance, acetyl fentanyl being sold as heroin (McIntyre, Trochta, Gary, 
Wright, & Mena, 2016; Stogner et al., 2014), paramethoxymethamphetamine (PMMA) or 
paramethoxyamphetamine (PMA) being sold as ecstasy/amphetamine (Dams et al., 2003; 
Martin, 2001; Vevelstad et al., 2012) or 4-methylamphetamine being sold as amphetamine 
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(Blanckaert et al., 2013). But research directed at the online NPS market has also seen 
instances of mislabelling which may be a cause for concern (Baron, Elie, & Elie, 2011; Elie, 
Elie, & Baron, 2013; McLaughlin et al., 2015; Zuba, Byrska, & Maciow, 2011).  
The mislabelling of NPS products calls for rigorous monitoring of the drug market through 
international pharmacovigilance, through systems such as the European Union Early Warning 
System (EMCDDA Europol, 2007). Some countries have implemented drug testing services 
to inform consumers and health care professionals, such as the DIMS in the Netherlands, 
WEDINOS in the UK and SINTES in France (Brunt et al., 2016; Brunt & Niesink, 2011; 
Giraudon & Bello, 2009; NHS Wales, 2015), about mislabelled, high-dosed or adulterated 
drugs. This may prevent dangerous substances from circulating on the streets and vendors 
withdrawing unwanted products more rapidly. One example of this occurred in the UK when 
5-IT was withdrawn from sales after it transpired that this compound was associated with 
severe adverse events, including deaths (European Monitoring Centre for Drugs and Drug 
Addiction, 2014b). Subsequently, this was followed by subjecting this substance to a ban 
(The Council of The European Union, 2013). 
Recent case reports have described the NBOMe-series of drugs being sold as LSD or 2C-
B (Gee, Schep, Jensen, Moore, & Barrington, 2016; Walterscheid et al., 2014), drugs that are 
pharmacologically active in different doses or administration routes. Individuals have been 
taking excessive doses of 25B-NBOMe, a much more potent substance, based on the believed 
purchase of 2C-B, resulting in hospital admissions due to severe adverse events (Gee et al., 
2016). 25I-NBOMe has also been sold as LSD and this has led to unfortunate incidents in the 
past (Kueppers et al., 2015; Shanks, Sozio, & Behonick, 2015; Walterscheid et al., 2014). 
The doses of 25B/C/I-NBOMe that were found on the blotters in the present study were 
usually considerably higher than equivalent doses of LSD on a blotter. Here, an average dose 
of 835 g/ blotter (maximum 1575 g) 25I-NBOMe was detected. Comparable doses were 
found in another recent toxicological study where several NBOMe derivatives were found on 
blotters (ranging from 510 g 25C-NBOMe to 1500 g 25B-NBOMe) (Poklis, Raso, Alford, 
Poklis, & Peace, 2015). Although detailed clinical studies are not available to assess dose-
response effects in humans, it has become increasingly clear that the toxicity associated with 
the known NBOMe derivatives is substantial (European Monitoring Centre for Drugs and 
Drug Addiction, 2014a; Hieger et al., 2015). 
The present study also showed a great variety in price between the different NPS and the 5 
I-TREND countries involved. Poland showed substantially lower prices of cathinones per 
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gram than the Netherlands or Czech Republic. Conceivably, this might be a direct reflection 
of the economic and welfare status, given that the average annual wage in Poland is much 
lower than that of the other countries participating in this study (International Labour 
Organization, 2015). Interestingly, nominal and PPP-adjusted prices of synthetic 
cannabinoids were substantially lower in the UK than in the other countries, which might be 
due to the legal status of these substances selected by the UK at the time of this project 
(European Commission, 2015; World Health Organization, 2015). As the sale of NPS 
probably happens from common suppliers throughout the globe, the controlling of some of 
the substances in the UK (e.g. methoxetamine, 25I-NBOMe, 6-APB) at the time of this study 
might have led to shifts in price in surrounding countries, like France or The Netherlands, 
since shipment to the UK was no longer an option.  
The absence of synthetic cannabinoids in the Netherlands might be the consequence of the 
liberal cannabis policy of the Netherlands, making good quality herbal cannabis widely 
available and suppressing the need for synthetic alternatives (MacCoun, 2011). The present 
results have revealed that two countries with a large NPS market (Poland and UK) offer very 
different quality of NPS. In Poland, despite the introduction of the blanket ban in 2010, the 
NPS market re-emerged in 2014 (Malczewski et al., 2015), with 100 brick and mortar stores. 
However, this has led to Poland having the highest amount of mislabelled NPS in this study. 
By contrast, in the UK the amount of mislabelled NPS was lowest. Moreover, the NPS purity 
levels were on the two extremes in these countries.  
It is important to note that the UK has adopted a new Psychoactive Substances Act starting 
in 2016 and this may have impacted on price and purity of the different NPS in this current 
study greatly since the Act has come into action (The Stationery Office, 2016). It was 
predicted by the UK Home Office that this Act will end the legal sale of NPS from street 
retailers and UK-based websites. The possibility of a displacement effect to purchasing from 
the dark web, the domestic black market and purchasing NPS from international retailers, is a 
worthy consideration. It has to be mentioned that a large proportion of UK webshops was 
already hosted in the United States at the time of this study and this proportion might have 
conceivably grown since the new Psychoactive Substances Act (European Monitoring Centre 
for Drugs and Drug Addiction, 2016b). The impact of the Act has yet to be evaluated, but 
research exploring the impact of the Act on both the UK domestic market, and the European 
NPS market, would be a worthwhile follow-up study and a useful case study to explore the 
impact of legalisation in one country on the NPS market on others.  
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In an international multi-centre study like this there are some inherent shortcomings to 
consider. First of all, there were country-specific differences in webshops, some webshops 
were easily accessible and the ordering of substances unproblematic, but others were 
unreliable and did not ship the products ordered or did not ship to specific EU countries, 
which challenged some participating institutions. This caused for incomplete analyses and 
missing results. Secondly, in parallel with the running time of this project the Council of the 
European Union or the World Health Organisation (WHO) Expert Committee were working 
on legislative action towards certain NPS that had been selected by participating institutions 
to include for analysis. Reference standards for these NPS had already been ordered, but 
availability through Internet suddenly changed after the announcement of the bans. It is also 
important to bear in mind that whereas the webshops selected in this study were directed at 
the population of different countries, these webshops are hosted by international (and 
sometimes untraceable) servers and the products they offer are by no means necessarily in 
stock at a particular location, but rather on wholesale stock somewhere else (Grund, 
Vavrincikova, Fidesova, & Janikova, 2016). NPS trade takes place on a global level, which 
means that shops are merely offering what they believe is in demand or what is in stock at 
that time. National legislative action is likely to have a decisive impact on what NPS are 
offered through country-specific webshops.  
Also, some laboratory techniques have a higher sensitivity than others, so detection of 
minute concentrations of NPS is expected to vary between laboratories. This may have 
resulted in an underreporting of certain NPS or adulterants. The same applies to the use of 
spectral libraries, since more complete and current spectral libraries are expected to translate 
to greater detection rates and fewer false negatives. It is recommendable to have inter-
laboratory validation in the future to prevent erroneous results.  
 
Conclusion 
Taken together, the current study provides a snapshot of the purity, composition and price 
of NPS that were available between 2014-2015 in webshops directed at different European 
countries. Despite the fact that effects of most NPS are still poorly understood, it is clear that 
there is a potential danger of mislabelling or adulteration of these substances. This is an 
important consideration for those working in the field of acute prevention and addiction care. 
The present findings are important to those studying the drug market in general by helping to 
understand how different NPS are marketed in different countries and the great variety in 
15 
 
price and purity of delivered products, which might be the result of the complex interaction of 
market dynamics and the role of law enforcement. 
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Table 1  
The 31 NPS that were selected and test purchased for this study, abbreviations, chemical classes and main effect are given. 
NPS 
 
    
Chemical class Chemical name Main abbreviation 
(chemical) 
Other names Main effect 
     
Aminoindanes 2-Aminoindane 2-AI
#
  Stimulant 
 N-Methyl-2-aminoindane NM-2-AI
#
  Stimulant 
Arylalkylamines 5-(2-Aminopropyl)indole 5-IT 5-API Stimulant/ 
Hallucinogen 
 5-(2-Aminopropyl)benzofuran 5-APB Benzofury Entactogen 
 6-(2-Aminopropyl)benzofuran 6-APB Benzofury Entactogen 
 1-(Benzofuran-5-yl)-N-ethylpropan-2-amine 5-EAPB
#
  Entactogen 
 Methiopropamine MPA  Stimulant 
Arylcyclohexylamines Methoxetamine MXE Mexxy, M-ket Dissociative 
Benzodiazepines Etizolam Etizolam Etilaam, Etizest Depressant 
Cathinones 3-Chloromethcathinone 3-CMC Meta-clephedrone Stimulant 
 3,4-Dimethylmethcathinone 3,4-DMMC  Stimulant 
 3-Methylmethcathinone 3-MMC  Stimulant 
 4-Methyl-N-ethcathinone 4-MEC NRG-2 Stimulant 
 -Pyrrolidinopentiophenone -PVP Flakka Stimulant 
 Ethcathinone ETH-CAT Ethcathinone Stimulant 
 3,4-Methylenedioxypyrovalerone MDPV NRG-1 Stimulant 
 4-Methyl-α-pyrrolidinopropiophenone MPPP  Stimulant 
 4-Bromomethcathinone 4-BMC Brephedrone  Stimulant 
 -Methylamino-valerophenone  Pentedrone Stimulant 
Diarylethylamines Methoxphenidine MXP
#
  Dissociative 
Indolalkylamines 5-Methoxy-N,N-diallyltryptamine 5-MeO-DALT
#
  Hallucinogen 
 -Methyltryptamine AMT 3-IT Stimulant/ 
Hallucinogen 
22 
 
Phenethylamines 2-Fluoromethamphetamine 2-FMA  Stimulant 
 4-Fluoroamphetamine 4-FA Flux, 4-FMP Stimulant 
 Ethylphenidate EPH  Stimulant 
 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl] 
ethanamine 
25I-NBOMe N-bomb, Cimbi-5 Hallucinogen 
Synthetic cannabinoids N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-
carboxamide 
5F-AKB48
#
 5F-APINACA Cannabis-like 
 1-Pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester 5F-PB22  Cannabis-like 
 N-(Adamantan-1-yl)-(1-pentyl)-1H-indazole-3-carboxamide  AKB48 APINACA Cannabis-like 
 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole  AM-2201  Cannabis-like 
 (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone UR-144 YX-17 Cannabis-like 
#
 These were follow-up substances after the UK ban of substances initially selected. 
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Table 2  
The list of different NPS products that were obtained by the different partner countries 
(number of purchases is given). 
 The 
Netherlands 
United 
Kingdom 
France Poland Czech 
Republic 
Total 
Substance name 
(NPS) 
N N N N N N 
       
2-AI* 0 8 0 0 0 8 
2-FMA 0 0 0 0 2 2 
3-CMC 0 0 0 0 1 1 
3-MMC 3 0 0 2 3 8 
3,4-DMMC 0 0 0 3 0 3 
4-FA 9 0 0 0 0 9 
4-MEC 4 0 0 0 0 4 
5-APB 1 0 4 0 0 5 
6-APB 6 0 3 0 0 9 
5-EABP* 1 8 0 0 0 9 
5F-AKB-48 0 8 0 0 0 8 
5F-PB-22 0 0 0 0 2 2 
5-IT 2 0 0 0 0 2 
5-MeO-DALT* 0 8 3 0 0 11 
25I-NBOMe 5 0 1 0 0 6 
-PVP 0 0 0 2 2 4 
AKB-48 0 4 0 0 0 4 
AM-2201 0 0 2 2 1 5 
AMT 0 8 0 0 1 9 
Brephedrone 0 0 0 1 0 1 
Ethcathinone 0 0 0 4 0 4 
Ethylphenidate 0 8 4 0 3 15 
Etizolam 0 8 0 0 0 8 
MDPV 4 0 0 0 0 4 
Methoxetamine 6 0 0 0 0 6 
Methoxphenidine* 0 8 0 0 0 8 
MPA 0 8 0 0 1 9 
MPPP 0 0 0 1 0 1 
N-Methyl-2AI* 0 8 0 0 0 8 
Pentedrone 0 0 0 2 3 5 
UR-144 0 0 2 2 0 4 
Total 41 84 19 19 19 182 
* These were follow-up substances after the UK ban of substances initially selected. 
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Table 3 
Synthetic cathinone prices per country (EUR), given in absolute, purity adjusted  
and purchased power parities (PPPs). 
 
The Netherlands Poland Czech Republic 
  
Price per 
gram  
PPP 
adjusted  
Price per 
gram  
PPP 
adjusted  
Price per 
gram  
PPP 
adjusted  
 
23,84 22,05 8,33 12,54 16,47 25,45 
purity 
adjusted 33,58 31,05 14,12 21,26 19,60 30,29 
stdv 6,07 5,62 2,06 3,07 4,13 11,47 
 
 
Table 4 
Synthetic cannabinoid prices per country (EUR), given in absolute, purity adjusted and 
purchased  
power parities (PPPs). 
 
United Kingdom France Poland Czech Republic 
  
Price per 
gram  
PPP 
adjusted  
Price per 
gram  
PPP 
adjusted  
Price per 
gram  
PPP 
adjusted  
Price per 
gram  
PPP 
adjusted  
price 11,36 7,07 16,00 15,08 14,12 21,05 18,10 26,76 
purity 
adjusted 12,08 7,52 24,62 23,20 23,94 35,69 21,55 31,86 
stdv 0,95 0,59 - - 1,87 2,79 1,37 2,02 
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Legends to figures: 
Fig. 1. Average purity of NPS detected over multiple webshop test purchases, number is depicted between brackets. Substances by effect, 
stimulants (1), entactogens (2), hallucinogens (3), dissociatives (4), cannabis-like (5).  
 
Fig. 2. Products test purchased online which contained the NPS as labelled or contained a NPS of the same chemical class or contained a NPS of 
a different chemical class.  
 
Fig. 3. Average prices of NPS products per gram, number of purchases is depicted between brackets. These price were not adjusted for purity, 
since some products did not contain the advertised compound. Error bars represent ± standard deviation. 
 
Table S5 
Overview of laboratory* methods utilized by the different partner countries. 
METHODS France Poland 
Czech 
Republic 
UK Netherlands 
(LC/ESI/QToF)          
(LC/ESI/MS/MS)        
(LC/ESI/MS)       
(LC/DAD)      
GC/FID)      
(GC/MS)        
(GC/MS/MS)         
 
*Partner laboratories: France, Laboratoire de Toxicologie & Génopathies Lille Hospital; Poland, 
National Medicines Institute 30/34 Chelmska str, 00-725 Warsaw; Czech Republic, Police of the 
Czech rep., Institute of Criminalistics Prague; UK, Dr. Roland Archer States Analyst's Laboratory, 
Longue Rue St. Martin's Guernsey; Netherlands, DSM Resolve, Gate 5 Kerenshofweg 101, Geleen. 
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